Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
14.7M
-
Shares change
-
-715K
-
Total reported value, excl. options
-
$99.5M
-
Value change
-
-$5.38M
-
Put/Call ratio
-
0.54
-
Number of buys
-
24
-
Number of sells
-
-41
-
Price
-
$6.74
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q3 2021
81 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q3 2021.
NextCure, Inc. - Common Stock (NXTC) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.7M shares
of 28M outstanding shares and own 52.61% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), BlackRock Inc. (1.23M shares), VANGUARD GROUP INC (807K shares), SILVERARC CAPITAL MANAGEMENT, LLC (721K shares), MILLENNIUM MANAGEMENT LLC (586K shares), FEDERATED HERMES, INC. (527K shares), Ikarian Capital, LLC (509K shares), CITADEL ADVISORS LLC (397K shares), and RENAISSANCE TECHNOLOGIES LLC (374K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.